ArticleUpdates in surgery2025
Does perioperative hydrocortisone reduce morbidity after pancreatoduodenectomy? A propensity score matched analysis.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-Pancreatectomy Acute Pancreatitis in Pancreatic Cancer: A Single-Center Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Pancreatic ductal adenocarcinoma and pancreatic surgery in the 21st century: triumphs, turning points, and unresolved challenges.Updates in surgery · 2026Review
- Advocating biomarker-guided perioperative hydrocortisone therapy to reduce morbidity after pancreatoduodenectomy.Updates in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of steroids in pancreatic surgery may reduce complications through the anti-inflammatory potential. We aimed to evaluate the impact of hydrocortisone (HC) on postoperative morbidity after pancreatoduodenectomy (PD). The data were retrospectively extracted from a prospective clinical database. Complicatons after PD with 100 mg HC intravenously (i.v.) for 48 h and a corresponding propensity score-matched cohort without HC were evaluated by using logistic regression analyses. We analyzed 691 patients who underwent PD over a period of ten years. After propensity score matching, 220 patients (110 patients in each group) remained. Postoperative complications were comparable in both groups (p = 0.56). Major complications (CDC ≥ 3) did not differ significantly, n = 44 (40%) for non-HC n = 45 (40.9%) and HC group (p = 0.89). There was no difference (p = 0.88) in the POPF incidence, non-HC, n = 31 (28.2%) and HC group, n = 30 (27.3%). After stratifying for fistula risk score (FRS), results remained equal and no difference was observed in CDC ≥ 3 in the low (p = 1), intermediate (p = 0.82) and high-risk (p = 0.74) group. HC has been suggested to be effective in reducing postoperative morbidity, but the evidence is controversial. The benefit of HC in reducing postoperative complications after pancreatoduodenectomy cannot be supported in the present study.
Indexed as
Identifiers
40684420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.